TSC2 and brain neoplasm: In the study of Bongaarts [29] nineteen of 34 (56%) brain tumor samples had mutations in TSC2, 10 (29%) had mutations in TSC1, while five (15%) had no mutation identified in TSC1/TSC2. The majority of these samples had a loss of heterozygosity in the same gene in which the primary mutation was identified.